PROACTIVE: Tailored pain relief for musculoskeletal and arthritis-related movement pain
Official title: Testing the Pain Relief of musculOskeletal conditions and Arthritis using Carefully Tailored InterVEntions (PROACTIVE) Intervention: A Randomized Controlled Trial
Funded at University of Florida · NIH-11369050 · Data updated 2026-11-12
A tailored pain self-management program offering education, a resource toolkit, active prayer, and financial counseling for adults with chronic movement-related musculoskeletal pain.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Florida NIH-funded |
| Lab location | 1 site (Gainesville, United States) |
| Project start | June 1, 2024 |
| Project end | March 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $332,450 |
| NIH project number | 5R01NR021183-03 |
| Project ID | NIH-11369050 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults aged 21 and older with chronic musculoskeletal pain that worsens with movement who are willing to try non-drug self-management approaches would be ideal candidates.
✕Less likely to help
People with recent acute injuries needing immediate medical or surgical care, those requiring urgent opioid therapy, or those unable or unwilling to participate in self-management or spiritual components may not benefit.
What this research studies
You would be randomly assigned to either the PROACTIVE program or usual care and followed over time to see whether the program reduces pain when you move (movement-evoked pain). The PROACTIVE program combines focused pain self-management education, a practical toolkit of resources, an optional active prayer/spirituality component, and financial counseling about healthcare benefits. Researchers will measure movement-evoked pain, physical function, and other health factors such as health literacy and financial hardship to judge benefit. The intervention is designed to give older adults non-drug tools to manage pain and address real-life barriers to care.
Why it matters
Potential benefit: If successful, this program could reduce movement-related pain, improve mobility and daily functioning, and decrease reliance on long-term opioid or NSAID use.
How similar studies have gone: Prior pain self-management programs have shown mixed or small benefits and rarely focused primarily on movement-evoked pain, so combining tailored education with spirituality and financial counseling is a relatively new approach.
Where this research is happening
-
University of Florida
Gainesville, United States Active
Researchers
- Principal investigator: Booker, Staja — University of Florida
- Study coordinator: Booker, Staja
Related research
Other NIH-funded projects on the same topics.
-
Methotrexate for chronic arthritis after chikungunya infection
This research compares methotrexate to a placebo to see if it reduces joint inflammation and pain in people with long-lasting arthritis following chikungunya infection.
-
Using methotrexate to treat arthritis caused by chikungunya virus
This study is looking at how well methotrexate works for people with chronic arthritis that can happen after chikungunya virus infection, and it will help find better treatment options for this condition.
-
Using methotrexate to treat arthritis caused by chikungunya virus
This study is looking at how well methotrexate, a medicine often used for arthritis, works for people who have chronic arthritis after getting chikungunya virus, and it will help us understand if this treatment can make a difference in reducing their pain and inflammation.
-
Cognitive behavioral therapy and trazodone for insomnia phenotypes with high blood pressure
A clinical study tests how CBT-I and the sleep drug trazodone work for adults with insomnia and high blood pressure, focusing on a specific sleep duration pattern.
-
Gut microbes and methotrexate: boosting RA treatment through microbiome targets
Researchers are studying how gut bacteria affect how well methotrexate works for people with rheumatoid arthritis, aiming to make MTX effective for more patients.
-
Shorter antifungal treatment for kids with candidemia
A multi-center pediatric trial tests whether a shorter, 7 extra days of antifungal therapy after an initial 7 days is just as good as the standard 14-day approach for kids with candidemia who are improving on echinocandin therapy.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.